Rachel Dashiell looks at the two recent tops on the chart of Eli Lilly (LLY) as shares fall in the wake of a new Executive Order targeting prescription drug prices. She points to oversold momentum showing up in its RSI study. On a 3-year period, Rachel shows the overall upward trajectory but highlights a range between $975 to $710 taking place over the last year.